This 2021 review by Fisman and Tenenbaum discusses tirzepatide, a dual GIP and GLP-1 receptor agonist, as an innovative treatment for type 2 diabetes and obesity. Clinical trials, notably the SURPASS program, have demonstrated that tirzepatide significantly reduces HbA1c levels and body weight in a dose-dependent manner, outperforming existing therapies
